Holen Sie sich die Stockscreener-App
8.90
0.35%
-0.02
Schlusskurs vom Vortag:
$8.92
Offen:
$8.9
24-Stunden-Volumen:
862.05K
Relative Volume:
0.95
Marktkapitalisierung:
$468.22M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.603
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
-19.26%
1M Leistung:
-22.09%
6M Leistung:
+16.50%
1J Leistung:
+39.11%
1-Tages-Spanne:
$8.665
$9.025
1-Wochen-Bereich:
$7.81
$11.46
52-Wochen-Spanne:
$4.02
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.915 | 468.48M | 1.02B | -757.20M | -257.90M | -14.76 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.80 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.46 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.52 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
489.64 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Emergent BioSolutions announces appointment of John D. Fowler, Jr. to board of directors - marketscreener.com
Emergent BioSolutions Adds Independent Director Amid Turnaround Efforts - TipRanks
Emergent BioSolutions appoints John D. Fowler, Jr. as director and Audit and Finance Committee member - TradingView
John Fowler joins Emergent BioSolutions (NYSE: EBS) board, Audit role - Stock Titan
Emergent Biosolutions Announces Appointment Of John D. Fowler, Jr. To Board Of Directors - TradingView
Former Wells Fargo banker John Fowler joins Emergent BioSolutions board - Stock Titan
Emergent Biosolutions secures new contracts with Public Health Agency of Canada and Defence Department - Traders Union
EBS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Levels: Is Emergent BioSolutions Inc stock showing strong momentumPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Emergent BioSolutions Earnings: Revenue, Margins And GAAP Losses Paint Mixed Picture (EBS) - Seeking Alpha
Wall Street Zen Downgrades Emergent Biosolutions (NYSE:EBS) to Buy - MarketBeat
Emergent Biosolutions Q4 Earnings Call Highlights - Yahoo Finance
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Emergent BioSolutions (EBS) Stock Falls on Disappointing Revenue Guidance - GuruFocus
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions Inc. (EBS): Investor Outlook Reveals 21.62% Potential Upside Amidst Challenging Revenue Growth - DirectorsTalk Interviews
Emergent BioSolutions Stock Pre-Market (-21%): Q4 Revenue Miss & Weak NARCAN Sales - Trefis
Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue Challenges - GuruFocus
Emergent BioSolutions Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:EBS) 2026-02-26 - Seeking Alpha
Emergent Biosolutions: Q4 Earnings Snapshot - theheraldreview.com
Emergent BioSolutions authorizes $50M stock buyback program By Investing.com - Investing.com Australia
Earnings call transcript: Emergent Biosolutions Misses Q4 2025 Expectations, Stock Edges Up - Investing.com
Emergent BioSolutions (EBS) Projects Significant Growth in FY26 Earnings - GuruFocus
Emergent BioSolutions (EBS) Eyes Global Expansion and Growth Ini - GuruFocus
Emergent BioSolutions Q4 2025 slides: transformation advances despite revenue miss - Investing.com
Emergent BioSolutions secures $140M contracts with Canada - Investing.com Canada
Emergent BioSolutions (EBS) Secures Major Contracts with Canada - GuruFocus
Emergent BioSolutions (EBS) Reports Q4 Revenue Miss Amid Product - GuruFocus
Emergent BioSolutions (EBS) Approves $50M Stock Repurchase Plan - GuruFocus
Emergent BioSolutions (NYSE: EBS) outlines 2025 turnaround strategy - Stock Titan
Emergent Biosolutions (NYSE:EBS) Releases Quarterly Earnings Results - MarketBeat
Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround - TipRanks
Emergent BioSolutions authorizes $50M stock buyback program - Investing.com
Earnings Summary: Emergent BioSolutions Q4 - Benzinga
Emergent BioSolutions Inc. announces an Equity Buyback for $50 million worth of its shares. - marketscreener.com
Naloxone maker Emergent BioSolutions posts $52.6M profit after $190.6M loss - Stock Titan
Emergent BioSolutions lines up $50M for stock buybacks through 2027 - Stock Titan
Emergent Biosolutions: Fourth Quarter Financial Overview - Bitget
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program - Bitget
Three AI Analyst Stocks, LSBK, EBS, and MNSO, Projected to Rise Over 20% - Intellectia AI
How dovish Fed policy supports Emergent BioSolutions Inc. (ER4) stock2025 Trading Volume Trends & Stock Portfolio Risk Management - mfd.ru
Emergent BioSolutions Inc. (EBS) Stock Analysis: Navigating a 22.84% Potential Upside Amidst Healthcare Challenges - DirectorsTalk Interviews
NY Attorney General Brings Action Against Former Emergent BioSolutions CEO - marketscreener.com
Aug Mood: Is Emergent BioSolutions Inc stock showing strong momentumJuly 2025 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Emergent BioSolutions Inc. (EBS) Stock Analysis: A 24% Potential Upside Amid Strategic Healthcare Solutions - DirectorsTalk Interviews
Monday's Underperformers: Auto Dealerships and Biotechnology Shares - Intellectia AI
NY Attorney General brings action against former Emergent BioSolutions CEO - Herbert Smith Freehills Kramer
What's Going On With Emergent BioSolutions Friday?Emergent BioSolutions (NYSE:EBS) - Benzinga
Emergent BioSolutions Says FDA Approves Supplemental NDA for Nasal Spray Product - marketscreener.com
Emergent BioSolutions (EBS) Expands NARCAN Nasal Spray Offering with FDA Approval - GuruFocus
New NARCAN 6- and 24-packs approved to aid large-scale overdose preparedness - Stock Titan
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):